Kissei Pharmaceutical has reported that it is to stop developing amiprilose HCl, an antirheumatic agent it licensed from US company Greenwich Pharmaceuticals.
The company states that the results of double-blind clinical trials in chronic rheumatoid arthritis patients revealed that the agent's effects failed to meet expectations. As a consequence of these results, it appears that the agent may not meet the standards required and so development of the drug has been halted.
- Meantime, Kissei has entered into an agreement with Wakunaga Pharmaceutical for the development and marketing of WK-1492-2K, a new non-competitive angiotensin II receptor anatagonist.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze